The Pfizer and Johnson & Johnson-backed cancer treatment developer is eyeing expansion in Asia after receiving $40m in additional series D funding.

The Mitsui and Intel-backed cloud video platform developer has filed to go public having last raised money five years ago.

An unnamed care provider has added $20m to the $80m the software-based therapeutics developer received from investors including Novartis and SoftBank in December.

Access Biotechnology and returning investor Eli Lilly were among the participants in a series B round for the RNA-based drug developer.

OneTrust has acquired DocuVision, providing exits to investors including Berkeley SkyDeck Fund and Oxford Seed Fund.

Susquehanna International Group looks set to exit the microbiome therapeutics developer, which has filed to raise up to $100m in its initial public offering.

Pfizer Ventures could be in line for an exit after AbbVie purchased a buyout option for Parkinson's disease drug developer Mitokinin.

Acorn Bioventures has led a series B round for the cancer-focused biopharmaceutical spinout of CU Boulder.

Sumitomo Corporation of Americas and Ingka Investments helped the on-demand commercial vehicle provider close its series A round.

AbbVie has bought an exclusive option to acquire Mitokinin once the UCSF spinout completes IND-enabling studies for its Parkinson’s treatment.